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A B S T R A C T   
Autosomal recessive osteopetrosis (ARO) is rare, involving increased bone density due to defective osteoclast 
differentiation or function, with several genetic subtypes. 
Case: This child with compound heterozygous novel loss-of-function TNFRSF11A pathogenic variants causing 
osteoclast-poor ARO underwent haematopoietic stem cell transplantation (HSCT) aged 3.1 years and experienced 
episodic severe hypercalcaemia over 2.5 years. She initially presented aged 8 months with craniosynostosis and 
visual impairment and underwent surgery; no increased bone density evident on skull imaging nor variants in 
genes associated with craniosynostosis identified. She was subsequently referred for investigation of poor linear 
growth and low alkaline phosphatase. Clinical abnormalities included asymmetric pectus carinatum, thickened 
anterior tibia and wrists, and markedly delayed dentition. Skeletal survey revealed generalised osteosclerosis 
with undertubulation. 
Management: She received haploidentical HSCT aged 3.1 years and developed hypercalcaemia (adjusted calcium 
4.09mmol/L = 16.4mg/dL) Day 18 post-HSCT, unresponsive to hyperhydration and diuretics. Denosumab 
achieved normocalcaemia, which required 0.6mg/kg every 6 weeks long-term. The ensuing 2.75 years feature 
full donor engraftment, good HSCT graft function, skeletal remodelling with 2.5 years recurrent severe hyper-
calcaemia and nine fragility long bone fractures. 
Conclusion: This case illustrates challenges of bone and calcium management in ultrarare TNFRSF11A-related OP- 
ARO. Craniosynostosis was an early feature, evident pre-sclerosis in osteopetrosis. Following HSCT, restoration 
of osteoclast activity in the context of elevated bone mass produced severe and prolonged (2.5 years) hyper-
calcaemia. Denosumab was effective medium-term, but required concurrent long duration (11 months) zole-
dronic acid to manage recurrent hypercalcaemia. Fragility fractures brought appreciable additional morbidity in 
the post-HSCT phase.   
1. Introduction 
Autosomal recessive osteopetrosis (ARO) is rare (1:250,000), usually 
presents in infancy, requiring prompt diagnosis to facilitate early hae-
matopoietic stem cell transplantation (HSCT) where appropriate (Wu 
et al., 2017). Hypercalcaemia can emerge once HSCT for ARO restores 
osteoclast activity (Martinez et al., 2010). Whilst hypercalcaemia may 
occur in various types of ARO, it is especially the case in the osteoclast- 
poor forms and can be particularly severe in the OP-ARO subtype due to 
mutations in the Tumour Necrosis Factor Receptor Superfamily 11A 
(TNFRSF11A) gene, which encodes the protein Receptor Activator of NF- 
kB (RANK) (Shroff et al., 2012; Pangrazio et al., 2012; Paul et al., 2019). 
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Rapid onset severe hypercalcaemia is a medical emergency: patients 
can be unwell, thirsty, dehydrated and have abdominal pain; compli-
cations include pre-renal renal failure, nephrocalcinosis and long-term 
renal impairment (Martinez et al., 2010). So, vigilance in calcium 
monitoring and appropriate management of hypercalcaemia is required. 
The monoclonal antibody denosumab mimics osteoprotegerin action 
by blocking RANK ligand (RANKL) binding to RANK receptor, thus 
inhibiting osteoclast differentiation, activity, and bone resorption. The 
mean half-life of denosumab from adult data is 29 days (range 25–35 
days). In vivo development of antibodies against denosumab that might 
influence efficacy has not been described. Functional inhibition of bone 
turnover rapidly reverses after drug discontinuation, in contrast to 
bisphosphonates which persist in bone (Boyce, 2017). Other case reports 
of denosumab use in children with refractory post-HSCT- 
hypercalcaemia with short to medium term follow-up (Shroff et al., 
2012; Pangrazio et al., 2012; Paul et al., 2019) suggest hypercalcaemia 
may resolve by 9–12 months allowing denosumab discontinuation. We 
report an extremely unusual and challenging OP-ARO case with longer 
duration (2.5 years post-HSCT) of problematic hypercalcaemia despite 
18 months of denosumab, then 12 months of adjuvant zoledronic acid. 
This case contributes new information on denosumab dose and fre-
quency in a <10 kg patient. It demonstrates that rebound hyper-
calcaemia may occur despite concomitant bisphosphonate therapy, and 
may be prolonged in the setting of markedly elevated bone mass. 
Osteoclast remodelling of osteopetrotic bone post-HSCT should 
ultimately lessen excessive bone mass, but our case illustrates the 
attendant risk of deleterious severe hypercalcaemia and the fragility 
fractures (due to low-energy trauma) highlight the underlying abnormal 
bone quality. This TNFRSF11A OP-ARO case illustrates the complexity 
of a bone metabolism medication strategy which optimally controls 
osteoclasts to resolve hypercalcaemia whilst sufficiently permissive of 
skeletal remodelling post-HSCT. This case also adds evidence to the 
literature that craniosynostosis may constitute an early feature of ARO. 
2. Case report 
A now 5.9-year-old girl was referred to paediatric endocrine services 
aged 2.3 years due to poor linear growth and concern around low 
alkaline phosphatase. She had no bone pain and consumed a normal 
calcium content diet. She was born at 41 weeks gestation with normal 
birth weight (3.57 kg), of mixed White British and British Asian 
ethnicity. During her early months she was assessed for a left intermit-
tent divergent squint, with otherwise normal developmental milestones 
and growth in infancy. She then presented aged 8 months with a bulging 
fontanelle and cranial imaging identified bilateral partial coronal cra-
niosynostosis without hydrocephalus. Plain radiograph imaging did not 
give evidence of any skull vault or skull base density increase (Fig. 1A). 
Ophthalmology assessment revealed nystagmus, left visual impairment 
and optic nerve pallor. CT imaging (not shown) did not give any evi-
dence of foraminal narrowing; it remained unclear whether the optic 
Fig. 1. Radiology: initial lateral skull plain radiograph aged 8 months on presentation with craniosynostosis; no increased density of either skull vault or skull base 
evident on this radiograph [A]. Remainder are skeletal survey plain radiographs at diagnosis of osteopetrosis aged 2.3 years; all show marked generalised increased 
density (B–J). B: Increased skull base density with skull vault sparing, previous skull vault surgical springs. C Chest X-ray: increased rib density, proximal humeral 
medullary lucencies. Spine shows mild platyspondyly and end-plate sclerosis and bone in bone appearance in the pelvis (lateral [D] and PA [E]). Hand and wrist [F]: 
increased density throughout all carpal, metacarpal and phalanges. Long bone images (humerus [G], radius and ulna [H], femur [I], tibia and fibula [J]) show loss of 
corticomedullary differentiation and undertubulation with prominent medullary lucencies in proximal and distal diaphyses. (Image [I] of the femur also shown in 
Fig. 3(last panel) for comparison to illustrate long bone growth between baseline and 2.5 years post-HSCT). 
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nerve dysfunction was due to raised intracranial pressure or a degree of 
foraminal narrowing or a combination thereof. Visual loss progressed. 
Craniofacial surgery was undertaken, involving posterior vault expan-
sion, due to progressive suture involvement (lambdoid and squamous 
sutures). Clinical examination aged 2.3 years showed significant short 
stature (height z score − 3.4 SDS, weight z score − 4.9 SDS, BMI 14.14 
kg/m2 [2nd centile], head circumference 46.6 cm[50th centile]), 
asymmetric pectus carinatum, mild facial asymmetry, markedly delayed 
primary dentition (only 3 erupted teeth), mild thickening and broad-
ening of wrists and anterior tibia, but no significant bowing or marked 
other deformity. She had severe but stable visual impairment, bilateral 
optic atrophy and retained light perception in left eye. 
Investigations: initial testing prior to the craniosynostosis surgery 
had shown a normal array CGH (Comparative genomic hybridization) 
and a craniosynostosis gene panel had identified no causative variants, 
including extended sequencing of TCF12, FGFR2 and ERF genes. 
Biochemistry investigations aged 2 years indicated persistently mildly 
low alkaline phosphatase (94–139 IU/L, reference range 156–369), 
normal full blood count, electrolytes and liver function. A skeletal sur-
vey aged 2.3 years revealed marked generalised increased density of the 
appendicular and axial skeleton, bone in bone appearance in the pelvis, 
long bones showed loss of corticomedullary differentiation and under-
tubulation with prominent medullary lucencies in proximal and distal 
diaphyses, and spine showed mild platyspondyly and end-plate sclerosis 
(Fig. 1 panels B–J). This radiological evidence suggested a form of 
osteopetrosis or ‘sclerosing skeletal dysplasia’, highlighting that osteo-
petrosis and dysosteosclerosis are overlapping entities. This case was 
diagnostically challenging, as the absence of initial osteosclerosis on 
imaging under one year of age, and the lack of hepatosplenomegaly and 
hypogammaglobulinaemia were consistent with dysosteosclerosis, 
whereas in our opinion the platyspondyly was much more minimal than 
typical for dysosteosclerosis. Molecular genetic testing was undertaken 
on a clinical basis by the Bristol Genetics Laboratory with a bespoke 
panel for osteopetrosis and osteosclerosis using Agilent’s Focused 
Exome custom target enrichment system SureSelectXT for the following 
21 genes: ANKH, CA2, CLCN7, CTSK, FAM123B, FAM20C, FERMT3, 
IKBKG, LEMD3, LRP5, OSTM1, SNX10, SOST, TCIRG1, TGFB1, 
PLEKHM1, PTH1R, RASGRP2, TNFRSF11A, TNFSF11, TYROBP, and 
variants confirmed using Sanger Sequencing. This revealed two com-
pound heterozygous variants in TNFRSF11A gene not reported in other 
patients: c.414_427 + 7del, p.(Gln140Alafs*17) (maternal, White British 
ethnicity) and c.1664del, p.(Ser555Cysfs*121) (paternal, British Asian 
ethnicity). These describe deletions predicted to cause frameshifts 
resulting in STOP codons 16 and 120 bps downstream respectively, 
resulting in reduced or absent TNFRSF11A expression and were classi-
fied as pathogenic and likely pathogenic respectively according to 
American College of Medical Genetics and Genomics (ACMG) Guidelines 
(Richards et al., 2015) and Association for Clinical Genomic Science 
(ACGS): c.414_427 + 7del [p.Gln140Alafs*17] (ACGS 2019 scoring PM2 
(moderate pathogenicity) absent gnomAD reference population, PVS1 
(Pathogenic Very Strong) nonsense mediated decay predicted due to 
disruption of donor site exon 4 of 10, not reported in other patients, 
pathogenic) and c.1664del [p.Ser555Cysfs*121] (ACGS 2019 scoring 
PM2 absent gnomAD reference population, PVS1_moderate nonsense 
mediated decay not predicted and <10% protein removed, not reported 
in other patients, likely pathogenic), consistent with Autosomal Reces-
sive Osteopetrosis (OP-ARO) (All TNFRSF11A sequence information is 
based on GenBank reference sequence NM_003839.3). The pathogenic 
variants in this case are also in Xue et al focussed on separate subsequent 
functional work, under the descriptor dysosteosclerosis, on the osteo-
petrosis spectrum (Xue et al., 2020). A pre-transplant Dual energy X-ray 
absorptiometry (DXA) scan using Hologic C confirmed markedly 
elevated Lumbar (L1-L4) Bone Mineral Density (BMD), Z-score + 6.3. 
Aged 3.1 years, she underwent a haploidentical-maternal HSCT, HLA 
matching 5/10, bone marrow stem cells (donor had normal bone min-
eral density). HSCT workup included IgG immunoglobulins 4.99 g/L 
normal for age. The conditioning regimen comprised rituximab, alem-
tuzumab, busulfan, fludarabine and cyclophosphamide. The CD34 cell 
dose administered was 4.29 × 106/kg. Hypercalcaemia (adjusted cal-
cium 3.0 mmol/L [2.20–2.70]) occurred on Day 18 post-HSCT, four days 
ahead of engraftment (Day 22) defined by the first of three consecutive 
days of neutrophils >0.5 × 109/L. Hyperhydration and diuretics for 36 h 
were ineffective and hypercalcaemia (Fig. 2) worsened to adjusted cal-
cium 4.09 mmol/L(16.4 mg/dL) with hypercalciuria (calcium creatinine 
ratio 12.30 [N < 0.8]). Denosumab 0.13 mg/kg (1.2 mg; weight 9.2 kg, 
open orange diamond in Fig. 2) subcutaneous injection was adminis-
tered on Day 20 post-HSCT. Administration details involved denosumab 
60 mg in 1 mL diluted to 10 mL with water-for-injection, of which 0.2 
mL (=1.2 mg) was injected. Serum calcium reduced minimally (4.09 to 
3.65 mmol/L), raising concern whether the denosumab dose was 
insufficient or involved incomplete delivery of the extremely small 
volume. An additional denosumab dose 0.2 mg/kg was administered 4 
days later, creating an effective total denosumab dose 0.33 mg/kg which 
normalised serum calcium (2.51 mmol/L) for 3 weeks. Thereafter 
symptomatic hypercalcaemia (increased thirst and abdominal pain) 
continued to recur after several weeks. On some occasions despite 
weekly to twice weekly biochemical monitoring, symptomatic hyper-
calcaemia developed extremely rapidly only a few days after a reas-
suring calcium level. It was therefore challenging to identify the ideal 
denosumab dosage regimen. Denosumab 0.25 mg/kg (2.4 mg, shaded 
orange diamonds in Fig. 2) every 4 weeks proved adequate and was 
transitioned to larger (0.6 mg/kg: solid orange diamonds in Fig. 2) less 
frequent (every 8 weeks) doses to reduce injection frequency burden to 
the child. Unfortunately, the larger dose did not increase duration of 
efficacy and symptomatic severe hypercalcaemia developed rapidly on 
four occasions, each involving emergency department presentation and 
inpatient admission (Days 51, 103, 227 and 272 post-HSCT, varying 
from 6.5 to 7.5 weeks following previous denosumab injection). Deno-
sumab was required and was consistently efficacious (hyperhydration 
achieved no improvement). From 9 months post-HSCT, dosing fre-
quency was changed to denosumab 0.6 mg/kg (6 mg) every 6 weeks, 
which proved effective for the following 12 months (Fig. 2). Hyper-
calcaemia was accompanied by appropriately suppressed PTH 0.6 
(normal range 1.6–6.9 pmol/L) and hypercalciuria (urine calcium: 
creatinine ratio 2.47 and 3.85 [normal range < 0.8]). Bone turnover 
markers (alkaline phosphatase [ALP], procollagen 1 N-Terminal Pro-
peptide [P1NP] and C-terminal telopeptide of type 1 collagen [CTX]) are 
shown in Fig. 3. Alkaline phosphatase (ALP), which was low prior to 
HSCT (indicated by blue arrow; consistent with the intrinsic low turn-
over rate of osteopetrosis) rose during episodes of hypercalcaemia post- 
HSCT but overall remained subnormal for 2 years post-HSCT; it has been 
more consistently in normal range over the last 10 months. Evidence of 
excess bone breakdown as the cause of the hypercalcaemia was obtained 
during five instances of hypercalcaemia demonstrated by elevated CTX 
0.94, 1.39, 0.99, 1.71 and 1.85 (normal range 0.1–0.5 μg/L) (see lower 
panel Fig. 3). CTX was assayed immediately prior and 48 h following 
denosumab falling from 0.99 μg/L (elevated) to 0.37 μg/L (normal), 
indicating expected response to denosumab (24 months post-HSCT). 
Tartrate Resistant Acid Phosphatase (TRAP5b) was 11.3 U/L 
(measured 27 months post-HSCT). 
By 18 months post-HSCT, it was expected that the excessive osteo-
clast activity responsible for hypercalcaemia might have abated allow-
ing denosumab to be withdrawn. We cautiously weaned denosumab, 
whilst overlapping with introduction of zoledronic acid intravenous 
infusions to mitigate the potential of the recognised phenomenon of 
rebound hypercalcaemia on denosumab withdrawal (Boyce, 2017). 
Despite serial zoledronic acid infusions and frequent monitoring, there 
was rapid onset of severe (3.81 mmol/L) and symptomatic hyper-
calcaemia 3 months after discontinuing denosumab (see Fig. 2). This 
rebound hypercalcaemia from denosumab-washout was treated with 
both denosumab and zoledronic acid, as was a further occurrence of 
rebound hypercalcaemia 6 weeks later (adjusted calcium 4.06 mmol/L) 
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(see Fig. 2); both episodes were associated with hypercalciuria (calcium: 
creatinine ratio 3.49 and 2.47, at 666 and 722 days (22 and 24 months) 
post-HSCT respectively). Ultimately, denosumab was administered for 
26 months, with zoledronic acid for the latter 8 months thereof. Sub-
sequent to final denosumab injection, two further episodes of significant 
hypercalcaemia (3.47 and 3.49 mmol/L) required zoledronic acid 0.025 
then 0.017 mg/kg infusions respectively. A further episode of mild 
hypercalcaemia (2.88 mmol/L) was monitored and resolved without 
intervention. The latest status is normocalcaemia for 3 months (6 
months since last denosumab and 4 months since last zoledronic acid). 
Nine fragility fractures occurred between 7 and 29 months post- 
HSCT (nil prior) (Fractures itemised in Table 1 and Radiology shown 
in Fig. 4). Fractures 1–8 were all low trauma fractures (fell from 
standing, or for fracture 6: twisted her foot), minimally displaced and 
managed conservatively. Fracture number 9 differed from previous in 
mechanism, location, type and intervention required: moderately 
greater trauma force (fell whilst slowly riding stability tricycle) resulted 
in an oblique fracture diagonally across an expanded remodelling 
diaphysis (encompassing diaphyseal new bone growth post-HSCT 
merging into pre-HSCT osteopetrotic diaphyseal region of femur). This 
displaced fracture required closed reduction under anaesthetic. All 
fractures demonstrated normal healing characteristics: clinical resolu-
tion within the usual timeframe for normal childhood fractures and with 
normal callus formation (Fig. 4 panel 2b). 
Beyond the above calcium and bone complications, overall progress 
post-HSCT proceeds well: there has been persistent 100% donor 
chimerism, normal blood counts, and no other transplant-related com-
plications. Aged 5.9 years, she attends mainstream school with visual 
impairment educational support. Residual vision has not deteriorated, 
and hearing remains stable. Linear growth demonstrates normal but not 
increased growth velocity, i.e. no catch-up growth has occurred: Height 
SDS -3.7 SDS both just prior to transplant and 2.6 years post-transplant. 
Appreciable reduction in BMD did not occur in the initial 1.5 years, but 
is evident 2.5 years post-HSCT (see Table 2). Lateral spine plain radi-
ography 2.4 years post HSCT is unchanged, showing neither progression 
from mild platyspondyly nor evidence of vertebral fractures. Renal ul-
trasound was normal pre-transplant, but mild nephrocalcinosis was 
identified 6 months post-HSCT and remains stable (bilateral grade 1 
nephrocalcinosis) on serial monitoring with normal renal function. 
3. Discussion 
Osteopetrosis is a heterogeneous group of rare skeletal disorders 
characterised by increased bone density due to defective osteoclast 
differentiation and function (Wu et al., 2017). Autosomal dominant 
forms can be relatively mild and usually diagnosed in adulthood, 
whereas autosomal recessive osteopetrosis (ARO) forms are more severe 
and typically present in infancy. Our case demonstrates several new 
learning points relevant to optimal clinical management of the ultrarare 
subtype of TNFRSF11A-related ARO (1–4% of cases of ARO). These 
include several notable ARO clinical features (failure to thrive, optic 
atrophy and dental abnormalities), unusual radiographic skeletal 
changes (specifically loss of corticomedullary differentiation, and 
prominent medullary lucencies in proximal and distal diaphyses), cra-
niosynostosis and fragility fractures. Three clinical aspects to highlight 
for further discussion are the initial cranial vault abnormalities, the post- 
Fig. 2. Episodes of post-HSCT hypercalcaemia, denosumab (orange diamonds ◆) and zoledronic acid (green squares ▪) administration and fractures (purple tri-
angles ▴) plotted against time (labelled as both days post-HSCT and age of patient). Serial serum adjusted calcium levels (blue line) plotted against x-axis of Days 
post-HSCT and age of patient, normocalcaemia (2.2–2.7 mmol/L) indicated by shaded blue range. Calcium data commences 2 week prior to the HSCT, and declines 
during pre-conditioning phase as expected, falling to mild hypocalcaemia by the time of HSCT (marked as Day 0), then onset of hypercalcaemia with engraftment 
(D18), with 12 further episodes of hypercalcaemia. Upper section of the figure illustrates denosumab subcutaneous injections (orange diamonds ◆, appearance 
(open, shaded, solid) and position indicating increased doses) and zoledronic acid infusions (green squares) out to 2.75 years post-HSCT. Lower section of the figure 
illustrates fracture episodes (purple triangles ▴). 
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HSCT hypercalcaemia and the fragility fractures. 
Recognised cranial abnormalities in ARO occur due to increased 
skull base bone mass causing hydrocephalus, which was not present in 
our case, and visual impairment from foraminal narrowing (Steward, 
2003). Although craniosynostosis is not widely considered as a charac-
teristic component of osteopetrosis, we identified 6 other individual case 
reports of craniosynostosis in ARO; genetic variants were reported for 
half the cases: TCIRG1 (n = 2) and OSTEM (n = 1), unreported (n = 3) 
(Driessen et al., 2003). We propose that craniosynostosis reflects 
reduced osteoclast activity giving abnormal bone modelling at cranial 
sutures and is relevant in identifying ARO, since craniosynostosis may 
present prior to obvious skeletal sclerosis. Our case highlights this 
diagnostic subtlety, as retrospective review of the initial skull radio-
graphs confirmed no apparent increase density of either skull vault or 
base in early infancy. 
The majority of ARO involve osteoclasts that are present but poorly 
functioning with compensatory positive feedback loops explaining the 
‘osteoclast-rich’ appearances on bone biopsy; genes involved are CA2, 
TCIRG1, CLCN7, OSTM1, PLEKHM1, SNX10 (Penna et al., 2019). In the 
rarer subgroup of OP-ARO, loss-of-function mutations prevent osteoclast 
formation, for which two causative genes have been identified: TNFSF11 
and TNFRSF11A. The cause of absent osteoclasts in TNFSF11-related 
ARO is the lack of RANKL to induce pre-osteoclast differentiation. By 
contrast, TNFRSF11A encodes the membrane-anchored RANK protein in 
the pre-osteoclast itself, without which pre-osteoclasts are intrinsically 
abnormal and unable to differentiate. This specific feature underpins the 
uniqueness of the TNFRSF11A-related OP-ARO as the type most likely to 
Fig. 3. Bone turnover markers: upper panel shows Alkaline phosphatase (ALP), which was low prior to HSCT (indicated by blue arrow) consistent with the intrinsic 
low turnover rate of osteopetrosis, then following HSCT rose at episodes of hypercalcaemia but overall remained subnormal for 2 years post-HSCT, then more 
consistently in normal range over last 10 months. The horizontal dashed orange line indicates the 26 months duration of denosumab and horizontal dashed green line 
indicates zoledronic acid which overlaps with 8 months of denosumab and indicates total zoledronic acid duration 11 months. Middle panel shows Procollagen N- 
Terminal Propeptide [P1NP] was normal on all occasions measured providing reassurance against excessive suppression. Lower panel shows C-terminal telopeptide 
of type 1 collagen [CTX] showed fluctuation with elevated results coinciding with episodes of hypercalcaemia (see text) with normalised levels after denosumab 
indicating appropriate osteoclast response to denosumab. Normal ranges indicated by green shading in all 3 panels. 
Table 1 
Nine fragility fractures occurred between 7 and 29 months post-HSCT.  
Fracture 
number 
Months 
post- 
HSCT 
Age 
(y) 
Fractures (nil 
pre-HSCT) 
Fracture details 
1 7  3.7 Left Clavicle Transverse proximal third of 
diaphysis 
2 12  4.1 Left humerus Transverse proximal third of 
diaphysis 
3 14  4.3 Left fibula Transverse proximal third of 
diaphysis 
4 16  4.4 Left tibia and 
fibula 
Transverse distal tibial 
diaphyses and minimal 
fracture lateral aspect of 
distal fibular diaphysis 
5 20  4.8 Right tibia 
and fibula 
Oblique distal third of tibial 
diaphysis 
Transverse distal third of 
fibula diaphysis 
6 24  5.2 Right 
metatarsals 
Transverse distal third of 
diaphyses of second and third 
metatarsals 
7 25  5.2 Right clavicle Transverse proximal third of 
diaphysis 
8 27  5.3 Left tibia Anterior portion of distal 
tibial metadiaphyseal region 
9 29  5.4 Left femur Oblique diagonal through 
distal-mid expanded region 
of diaphysis  
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involve severe hypercalcaemia following HSCT, as the transition from 
completely non-functional pre-osteoclasts to the engraftment of normal 
well-functioning RANK-secreting pre-osteoclasts permits a sudden in-
crease in osteoclast activity. Osteoclasts break down pre-existing excess 
bone, releasing significant circulating excess calcium. 
Life-threatening hypercalcaemia post-HSCT for OP-ARO is a known 
complication. Reported overall prevalence ranges from 16 to 40%, with 
higher risk 60% in patients older than 2 years of age attributed to their 
higher bone mass (Martinez et al., 2010; Shroff et al., 2012; Pangrazio 
et al., 2012; Driessen et al., 2003). In the OP-ARO subset (due to 
TNFRSF11A mutations), hypercalcaemia post-HSCT seems to have an 
even higher prevalence, earlier onset, and be both recurrent and more 
severe (Martinez et al., 2010; Penna et al., 2019). This presents clini-
cians with significant challenges regarding effective treatment options 
which until recently were limited to hyperhydration, furosemide, 
calcitonin, glucocorticoids, bisphosphonates and haemofiltration (Basok 
et al., 2018). 
The emergence of denosumab, first approved for use in adults in 
2010, as a potent anti-resorptive agent has provided an exciting new 
therapeutic option which more directly targets the pathophysiology of 
the hypercalcaemia. This human monoclonal antibody binds the RANK 
receptor with high affinity and specificity. It blocks RANKL binding, 
preventing osteoclast differentiation and hence reducing bone resorp-
tion. Denosumab is licensed for use in adults for post-menopausal 
osteoporosis, giant cell tumours, and hypercalcemia due to malig-
nancy and bone metastases (Boyce, 2017; Polyzos et al., 2019). There is 
emerging but cautious use of denosumab in paediatrics: clinical research 
trials in osteogenesis imperfecta (OI) and limited off-license use (Boyce, 
2017; Polyzos et al., 2019). Paediatric doses have differed widely: most 
commonly 1 mg/kg every 6 months, shorter intervals of 10 weeks in 
Type VI OI to manage breakthrough hypercalcaemia (Trejo et al., 2018) 
Fig. 4. Fragility fractures post-HSCT. Plain radiographs numbering corresponds with fracture episode chronology listed in Table 1. Arrows mark the fracture sites, in 
addition, all images show evidence of the underlying osteopetrotic changes of intra-medullary lucencies and diffuse sclerotic appearance similar to pre-HSCT evident 
in Fig. 1 images. 1: Left clavicle: transverse minimally displaced fracture through the medial third of the left clavicle diaphysis. 2a: Left humerus: transverse lucency 
across proximal third of humeral diaphysis. 2b is 7 weeks after image 2 and demonstrates proximal left humeral fracture with cortical remodelling, alignment 
preserved, sclerosed fracture plane and callus formation, pronounced on medial aspect. 3: left tibia and fibula: transverse fracture at proximal third of fibular 
diaphysis linear. 4: left tibia and fibula: upper arrow against proximal third of fibular diaphysis shows healing fracture from panel 3 and lower two arrows show new 
minimally displaced fractures through distal tibial and fibular diaphyses. 5: Right tibia and fibula: minimally-displaced oblique fracture of distal tibial diaphysis and 
an undisplaced transverse fracture of distal fibular diaphysis. 6: Right foot: non-displaced fracture through 2nd & 3rd metatarsals. 7 Right clavicle: Transverse 
fracture across proximal third. 8a Left tibia: fracture not evident on this AP image (so no arrow) whereas 8b (lateral image) shows non-displaced linear lucency 
evident through anterior distal tibia. 9 Left Femur: two arrows show upper and lower margins of oblique displaced fracture through expanded distal femoral 
diaphysis. This images 2.5 years post-HSCT also demonstrates improvement of metaphyseal contour and quality in comparison to pre-HSCT image to its right, with 
lessening of the medullary lucencies and loss of Erlenmeyer flask type deformity. 10: (lower right) does not contain a fracture but shown here in addition to Fig. 1 
(panel 1) to facilitate comparison of left femur diaphysis pre-HSCT against progressively changed in bone appearance post-transplant. 
Table 2 
Serial bone mineral density DXA scans, performed using Hologic C.  
Age 
(years) 
Years 
post- 
HSCT 
Whole body less head 
bone mineral density 
(g/cm2) 
Lumbar spine 
(L1–4) bone 
mineral density 
(g/cm2) 
Lumbar 
spine Z 
score  
2.8  Unavailable  0.934  +6.3  
4  0.9 Unavailable  1.052  +6.1  
4.6  1.5 0.689  1.133  +6.1  
5.6  2.5 0.625  1.055  +5.2  
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and a range of doses in different bone conditions; along with this rela-
tively frequent administration of 0.6 mg/kg every 6 weeks in post-HSCT 
hypercalcaemia in our case. 
Shroff et al first described denosumab to treat post-HSCT hyper-
calcaemia in two paediatric patients with OP-ARO due to TNFRSF11A 
mutations (Shroff et al., 2012). These patients were treated with deno-
sumab 0.13–0.27 mg/kg, appreciably lower doses than the 1 mg/kg 
regimen used in paediatric OI studies. In our small (<10 kg) patient, we 
elected to treat cautiously initially, using the lower dose 0.13 mg/kg 
(1.2 mg) subcutaneously. However, effective control of ongoing hyper-
calcaemia was not achieved until titration through several dosages to 
0.6 mg/kg once every 6 weeks for 18–24 months. This clinical efficacy 
duration of 6 weeks fits with evidence that bone turnover markers return 
to pre-treatment levels 6–8 weeks post denosumab (Boyce, 2017). The 
degree of rebound hypercalcaemia appeared uninfluenced by denosu-
mab dosage; the challenge was to reach duration of control that avoided 
overly frequent painful injections for this child. We propose use of 
denosumab 0.6 mg/kg at 6 week intervals, higher than previously re-
ported, in severe cases in the unique cohort of OP-ARO post-HSCT for 
medium-term control of hypercalcaemia. 
Commencing denosumab for RANK-related TNFRSF11A OP-ARO 
post-HSCT hypercalcaemia is an intuitive choice and is effective pre-
cisely because it directly targets the RANK signalling pathway now 
restored by HSCT. The temporary-reversible nature of denosumab was 
preferred over the potentially toxic bisphosphonate effect on engrafting 
stem cells. But this initial solution can be followed by the dilemma of 
how to safely discontinue. Upon ceasing denosumab, the monoclonal 
antibody no longer blocks the RANK pathway, unleashing a potentially 
amassed pool of pre-osteoclasts. Rebound hypercalcaemia is a recog-
nised complication following denosumab discontinuation in adults and 
children, particularly in high bone turnover conditions, e.g. giant cell 
tumours, Paget’s disease and fibrous dysplasia (Boyce, 2017). This 
rebound hypercalcaemia of denosumab washout was probably amplified 
by the underlying OP-ARO high bone mass, and hypothetically 
compensatory over-expression of RANKL proposed in RANK-related 
ARO (Sobacchi et al., 2013). These may all have contributed to severe 
hypercalcemia recurring whilst withdrawing denosumab, requiring 8 
months concurrent zoledronic acid to control. Elevated bone turnover 
marker CTX indicates bone breakdown, inferring osteoclast activity, 
common to all mechanisms. The serum tartrate resistant acid phospha-
tase (TRAP5b) 11.3 U/L may indicate reasonable osteoclast numbers at 
2.3 years post-HSCT; although there are neither reference ranges young 
children or young children with ARO post-HSCT, 11.3 is reassuringly 
close to 13–23 U/L (normal range 7.5-10 years (Whyte et al., 2010)). We 
hypothesise that longterm denosumab may have suppressed remodel-
ling (ALP normalisation took 2 years post-HSCT). However, the medical 
reality was dramatic hypercalcaemia causing systemic symptoms, where 
prompt control was essential to reduce risk of nephrocalcinosis pro-
gressing to renal impairment. Lower doses may have minimised sup-
pression, but they resulted in extremely frequent injections that were not 
tolerable for the child. Our case does raise the possibility that whilst 
denosumab is a rational solution for initial management it may 
perpetuate hypercalcaemia. So potentially addition of zoledronic acid 
earlier, e.g. after 8–12 months rather than 18 months, may be advisable. 
Overall, we attribute the extent of hypercalcaemia predominantly to the 
excessiveness of bone mass accumulated by the older age of transplant, a 
concept supported by the literature (Orchard et al., 2015). 
Restoration of osteoclast activity is an important outcome of HSCT 
for osteopetrosis. Skeletal remodelling in our case is indicated by 
hypercalcaemia and bone turnover markers. Progressive reduction of 
elevated bone mass is expected, although no other reports used DXA to 
quantify bone density. Our case highlights that reduction in DXA bone 
density may take a longer time frame to emerge - evident by 2.5 years, 
but not at 1.5 years post-HSCT (Table 2). Long duration of skeletal 
remodelling offloading excessive calcium can be attributed to the extent 
of excessive bone mass accumulated by older age at transplant (Orchard 
et al., 2015). We had considered whether transplantation from a hap-
loidentical donor rather than a homozygous normal donor did not 
achieve full bone correction. We discounted this hypothesis as HSCT is 
often done without apparent issue from parental or sibling carriers in 
other forms of osteopetrosis and secondly our maternal donor’s normal 
bone mineral density provides reassurance. Functional studies on this 
child’s pathogenic variants have very recently been published (Xue 
et al., 2020), giving some insight into osteoclast dysfunction mecha-
nisms and highlighting that osteopetrosis and dysosteosclerosis 
comprise a spectrum. Subsequent studies could further elucidate our 
unique case in due course. 
Our patient experienced 9 fragility fractures 7–29 months post-HSCT 
but none prior to transplant. This contrast pre and post HSCT may be 
coincidental, since fractures are a recognised feature of the natural 
history of osteopetrosis without stem cell transplant, due to the inher-
ently brittle marble-like bone (Sobacchi et al., 2013). Comparative post- 
HSCT fracture data is an acknowledged gap in follow-up studies (Or-
chard et al., 2015). It is plausible that the post-HSCT fractures are a 
consequence of bone turnover with normalised osteoclast function and 
bone physiology. It is notable that the long bone fractures in our case 
occurred at the junction of new diaphyseal bone growth post-HSCT with 
pre-existing ‘marble-like’ diffuse sclerotic bone (Figs. 1 and 4), poten-
tially where now restored osteoclast aims to remodel that abnormal 
bone. This junctional location is similar to ‘stress-riser’ fractures with 
bisphosphonate treated bone and medication-naïve bone. There is no 
evidence to indicate whether denosumab osteoclast inhibition increases 
or attenuates fracture risk in OP-ARO. Nevertheless, the impact of 
recurring fragility fractures was significant for this young child and 
influenced our pragmatic clinical decision to attempt to wean denosu-
mab and then zoledronic acid therapies to avoid ongoing bone sup-
pression and inhibition of bone remodelling. Since discontinuing both 
therapies, one episode of mild self-resolving hypercalcaemia suggests 
bone remodelling off-loading calcium. Ongoing surveillance will 
monitor bone quality improvement over the coming years. 
4. Conclusion 
Post-HSCT for OP-ARO, intrinsic osteoclast drive breaks down cal-
cium laden osteopetrotic bone, as remodelling strives to progressively 
normalise the skeleton. Our case demonstrates the challenge in 
achieving optimal treatment to permit sufficient bone turnover for 
skeletal remodelling, whilst sufficiently suppressing bone turnover to 
avoid life-threatening hypercalcaemia. Denosumab is effective for me-
dium term use in OP-ARO post-HSCT to combat recurrent hyper-
calcaemia. Thereafter, withdrawal is relevant to permit engrafted 
osteoclasts to facilitate skeletal remodelling. Judicious withdrawal en-
tails more than the single bisphosphonate administration to ‘seal in 
calcium’ effective in low bone mass conditions, e.g. OI, and involves 
prolonged concurrent zoledronic acid (8 months), during which vigi-
lance for rapid onset severe hypercalcaemia must be maintained. 
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